146 related articles for article (PubMed ID: 21797232)
1. Structure-based site of metabolism prediction for cytochrome P450 2D6.
Moors SL; Vos AM; Cummings MD; Van Vlijmen H; Ceulemans A
J Med Chem; 2011 Sep; 54(17):6098-105. PubMed ID: 21797232
[TBL] [Abstract][Full Text] [Related]
2. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
3. Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: predicting affinity and conformational sampling.
Bazeley PS; Prithivi S; Struble CA; Povinelli RJ; Sem DS
J Chem Inf Model; 2006; 46(6):2698-708. PubMed ID: 17125210
[TBL] [Abstract][Full Text] [Related]
4. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
5. Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking.
de Graaf C; Oostenbrink C; Keizers PH; van der Wijst T; Jongejan A; Vermeulen NP
J Med Chem; 2006 Apr; 49(8):2417-30. PubMed ID: 16610785
[TBL] [Abstract][Full Text] [Related]
6. A refined substrate model for human cytochrome P450 2D6.
de Groot MJ; Bijloo GJ; Martens BJ; van Acker FA; Vermeulen NP
Chem Res Toxicol; 1997 Jan; 10(1):41-8. PubMed ID: 9074801
[TBL] [Abstract][Full Text] [Related]
7. Prediction of sites of metabolism in a substrate molecule, instanced by carbamazepine oxidation by CYP3A4.
Yuki H; Honma T; Hata M; Hoshino T
Bioorg Med Chem; 2012 Jan; 20(2):775-83. PubMed ID: 22197672
[TBL] [Abstract][Full Text] [Related]
8. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.
Modi S; Paine MJ; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1996 Apr; 35(14):4540-50. PubMed ID: 8605204
[TBL] [Abstract][Full Text] [Related]
9. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
10. Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking.
Hritz J; de Ruiter A; Oostenbrink C
J Med Chem; 2008 Dec; 51(23):7469-77. PubMed ID: 18998665
[TBL] [Abstract][Full Text] [Related]
11. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
Kirton SB; Kemp CA; Tomkinson NP; St-Gallay S; Sutcliffe MJ
Proteins; 2002 Nov; 49(2):216-31. PubMed ID: 12211002
[TBL] [Abstract][Full Text] [Related]
12. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
[TBL] [Abstract][Full Text] [Related]
13. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase.
Modi S; Gilham DE; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1997 Apr; 36(15):4461-70. PubMed ID: 9109653
[TBL] [Abstract][Full Text] [Related]
14. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.
de Groot MJ; Ackland MJ; Horne VA; Alex AA; Jones BC
J Med Chem; 1999 May; 42(9):1515-24. PubMed ID: 10229622
[TBL] [Abstract][Full Text] [Related]
15. Analysis of CYP2D6 substrate interactions by computational methods.
Ito Y; Kondo H; Goldfarb PS; Lewis DF
J Mol Graph Model; 2008 Feb; 26(6):947-56. PubMed ID: 17764997
[TBL] [Abstract][Full Text] [Related]
16. Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site.
Berka K; Anzenbacherová E; Hendrychová T; Lange R; Mašek V; Anzenbacher P; Otyepka M
J Inorg Biochem; 2012 May; 110():46-50. PubMed ID: 22459173
[TBL] [Abstract][Full Text] [Related]
17. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
18. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts.
Rossato G; Ernst B; Smiesko M; Spreafico M; Vedani A
ChemMedChem; 2010 Dec; 5(12):2088-101. PubMed ID: 21038340
[TBL] [Abstract][Full Text] [Related]
19. Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: in silico predictions and experimental validation.
Keizers PH; de Graaf C; de Kanter FJ; Oostenbrink C; Feenstra KA; Commandeur JN; Vermeulen NP
J Med Chem; 2005 Sep; 48(19):6117-27. PubMed ID: 16162012
[TBL] [Abstract][Full Text] [Related]
20. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]